Evidence map›Paper›PMID 32916062›Full record

ArticleAnnals of the American Thoracic Society2020

Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States.

Sourya Shrestha, Andrea Parriott, Nicolas A Menzies, Priya B Shete, Andrew N Hill, Suzanne M Marks, David W Dowdy

Open access · greenAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the American Thoracic Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.0field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Sourya ShresthaJohns Hopkins Bloomberg School of Public Health Baltimore, Maryland.ORCID 0000-0002-6106-6834
Andrea ParriottUniversity of California San Francisco San Francisco, California.
Nicolas A MenziesHarvard T.H. Chan School of Public Health Boston, Massachusetts and.
Priya B SheteUniversity of California San Francisco San Francisco, California.ORCID 0000-0002-0279-8170
Andrew N HillCenters for Disease Control and Prevention Atlanta, Georgia.
Suzanne M MarksCenters for Disease Control and Prevention Atlanta, Georgia.
David W DowdyJohns Hopkins Bloomberg School of Public Health Baltimore, Maryland.
Centers for Disease Control and Prevention · USJohns Hopkins University · USUniversity of California, San Francisco · USHarvard University · US

Funding

ECONOMIC ANALYSIS FOR PREVENTION OF DISEASE (EMPoD)U38PS004649 · PS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAHN, JAMES GUSTAVE · 2014 to 2015
$3.0M
ENHANCING MODELS OF HIV, VIRAL HEPATITIS, STIs, AND TUBERCULOSIS TO INFORM AND IMPROVE PUBLIC HEALTH IMPACTU38PS004646 · PS · EMORY UNIVERSITY · PI SULLIVAN, PATRICK · 2014 to 2015
$2.9M
Economic Modeling for HIV, Viral Hepatitis, STD, TB and School HealthU38PS004644 · PS · HARVARD SCHOOL OF PUBLIC HEALTH · PI SALOMON, JOSHUA A · 2014 to 2015
$2.9M
NCHHSTP CDC HHS U38 PS004644NCHHSTP CDC HHS U38 PS004646NCHHSTP CDC HHS U38 PS004649
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Latent TuberculosisAntitubercular AgentsDrug Therapy, CombinationHumansIsoniazidRifampinUnited StatesAntitubercular AgentsIsoniazidRifampinrifapentine

Identifiers

PMID32916062
PMCPMC7923126
OpenAlexW3085964523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.